Literature DB >> 8312829

Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therapy. First results.

P Roggenkämper1, Z Nüssgens.   

Abstract

We performed frontalis suspension in 12 patients presenting with essential blepharospasm or "apraxia" of eyelid opening who did not respond sufficiently to botulinum toxin injections. An improvement could be observed in 9 patients. During the follow-up period (4-18 months) the effect of surgical intervention remained stable. As opposed to other surgical procedures (excision of the orbicularis muscle, resection of facial nerve branches), frontalis suspension can be considered as a minimally invasive and even reversible treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8312829

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  5 in total

1.  Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-28       Impact factor: 3.117

2.  Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.

Authors:  Dirk Dressler; Chrisanthi Karapantzou; Saskia Rohrbach; Simon Schneider; Rainer Laskawi
Journal:  J Neural Transm (Vienna)       Date:  2016-11-05       Impact factor: 3.575

3.  Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results.

Authors:  P Roggenkämper; Z Nüssgens
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

4.  Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results.

Authors:  Chrisanthi Karapantzou; Dirk Dressler; Saskia Rohrbach; Rainer Laskawi
Journal:  Head Face Med       Date:  2014-10-22       Impact factor: 2.151

5.  SURGICAL ASPECT OF BLEPHAROSPASM TREATMENT: A CASE REPORT.

Authors:  Kristijan Dinjar; Vedran Zubčić; Andrijana Kopić; Vlatko Kopić; Bruno Popić; Dubravka Holik
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.